Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Solara Active Pharma Sciences's Return-on-Tangible-Asset or its related term are showing as below:
NSE:SOLARAPP1'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -25.66 Med: -0.18 Max: 11.46
Current: -0.09
During the past 10 years, Solara Active Pharma Sciences's highest Return-on-Tangible-Asset was 11.46%. The lowest was -25.66%. And the median was -0.18%.
NSE:SOLARAPP1's Return-on-Tangible-Asset is ranked worse than 63.72% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.085
vs NSE:SOLARAPP1: -0.09
Solara Active Pharma Sciences (NSE:SOLARAPP1) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Solara Active Pharma Sciences Return-on-Tangible-Asset Related Terms
Solara Active Pharma Sciences Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences Return-on-Tangible-Asset Chart
NSE:SOLARAPP1 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solara Active Pharma Sciences Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Solara Active Pharma Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 3.35% mean?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a Return-on-Tangible-Asset of 3.35% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Solara Active Pharma Sciences and its competitors. According to the industry distribution chart, Solara Active Pharma Sciences ranks #641 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 63.7%.
Is Solara Active Pharma Sciences' Return-on-Tangible-Asset too high?
Solara Active Pharma Sciences' current Return-on-Tangible-Asset is 3.35%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.09. Solara Active Pharma Sciences' value of 3.35% is 8.6% above this industry median. Based on the distribution chart, Solara Active Pharma Sciences ranks #641 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Solara Active Pharma Sciences has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Solara Active Pharma Sciences ranks #641 out of 1006 companies for Return-on-Tangible-Asset. This places Solara Active Pharma Sciences in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.09. Solara Active Pharma Sciences' value of 3.35% is 8.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.09, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solara Active Pharma Sciences's current Return-on-Tangible-Asset of 3.35% is 8.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Solara Active Pharma Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solara Active Pharma Sciences's current Return-on-Tangible-Asset is 3.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a current Return-on-Tangible-Asset of 3.35%. The stock's GF Value™ is ₹279.65, compared to a current price of ₹267.45 — trading 4.4% below its estimated fair value. The current Return-on-Tangible-Asset is 3.35% and 8.6% above the Drug Manufacturers industry median of 3.09. Solara Active Pharma Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARAPP1), the current Return-on-Tangible-Asset is 3.35% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solara Active Pharma Sciences (NSE:SOLARAPP1) Overvalued in 2026?
Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be undervalued.
The current stock price of ₹267.45 is trading 4.4% below its estimated GF Value™ of ₹279.65.
Key valuation signals for NSE:SOLARAPP1:
Return-on-Tangible-Asset: 3.35%
GF Value™: ₹279.65 vs. price of ₹267.45 (4.4% below fair value)
Industry Position: 8.6% above the Drug Manufacturers median (#641 of 1006)
No single metric tells the full story. See the NSE:SOLARAPP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
69GF Score
Get the complete analysis for NSE:SOLARAPP1
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOLARAPP1 has been successfully added to your 
